文献速递其他结缔组织病

伊洛前列素逆转硬皮病血管功能障碍的细胞机制

Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma.
PubMed 文献 · Arthritis Rheumatol · 2021-02-08

该研究分离系统性硬化症(SSc)患者与健康对照的真皮内皮细胞,发现SSc内皮细胞黏附连接破坏、通透性增加。伊洛前列素可增强VE-钙黏蛋白聚集、恢复连接水平,并降低通透性、促进血管管腔形成、阻断内皮间质转化,为伊洛前列素治疗SSc雷诺现象和指端溃疡提供机制依据。

要点

  • SSc真皮内皮细胞黏附连接破坏,VE-钙黏蛋白减少且通透性增加。
  • 伊洛前列素增强VE-钙黏蛋白在连接处的聚集并恢复其水平。
  • 伊洛前列素降低内皮单层通透性、促进管腔形成并阻断EndoMT。

核心结论

  • 伊洛前列素的持久疗效可能源于其稳定黏附连接,从而增加管腔形成和屏障功能并减少EndoMT。

研究设计与样本

  • 研究分离SSc患者与健康对照的真皮内皮细胞,采用免疫荧光、通透性实验、Matrigel管腔形成实验和定量PCR检测伊洛前列素对内皮细胞的影响。

主要发现

  • SSc内皮细胞黏附连接破坏,表现为VE-钙黏蛋白水平降低且通透性增加(P < 0.05)。
  • 伊洛前列素孵育2小时后,SSc内皮细胞连接处VE-钙黏蛋白聚集增加,连接处VE-钙黏蛋白水平恢复至37.3 ± 4.3荧光单位,高于正常内皮细胞的29.7 ± 3.4荧光单位(P < 0.05)。
  • 伊洛前列素降低单层通透性、增加管腔形成并阻断正常与SSc内皮细胞的EndoMT(n ≥ 3;P < 0.05)。
  • 在正常内皮细胞中,上述效应可被阻止VE-钙黏蛋白连接聚集的功能阻断抗体抑制。

临床怎么用

  • 该机制支持伊洛前列素用于治疗SSc患者的雷诺现象和指端溃疡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Intravenous iloprost improves Raynaud's phenomenon (RP) and promotes healing of digital ulcers in systemic sclerosis (SSc; scleroderma). Despite a short half-life, its clinical efficacy lasts weeks. Endothelial adherens junctions, which are formed by VE-cadherin clustering between endothelial cells (ECs), regulate endothelial properties including barrier function, endothelial-to-mesenchymal transition (EndoMT), and angiogenesis. We undertook this study to investigate the hypothesis that junctional disruption contributes to vascular dysfunction in SSc, and that the protective effect of iloprost is mediated by strengthening of those junctions. METHODS: Dermal ECs from SSc patients and healthy controls were isolated. The effect of iloprost on ECs was examined using immunofluorescence, permeability assays, Matrigel tube formation, and quantitative polymerase chain reaction. RESULTS: Adherens junctions in SSc were disrupted compared to normal ECs, as indicated by reduced levels of VE-cadherin and increased permeability in SSc ECs (P < 0.05). Iloprost increased VE-cadherin clustering at junctions and restored junctional levels of VE-cadherin in SSc ECs (mean ± SD 37.3 ± 4.3 fluorescence units) compared to normal ECs (mean ± SD 29.7 ± 3.4 fluorescence units; P < 0.05), after 2 hours of iloprost incubation. In addition, iloprost reduced permeability of monolayers, increased tubulogenesis, and blocked EndoMT in both normal and SSc ECs (n ≥ 3; P < 0.05). The effects in normal ECs were inhibited by a function-blocking antibody that prevents junctional clustering of VE-cadherin. CONCLUSION: Our data suggest that the long-lasting effects of iloprost reflect its ability to stabilize adherens junctions, resulting in increased tubulogenesis and barrier function and reduced EndoMT. These findings provide a mechanistic basis for the use of iloprost in treating SSc patients with RP and digital ulcers.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Tsou PS, Palisoc PJ, Flavahan NA, et al. Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma. Arthritis Rheumatol. 2021. PMID: 33001586. doi:10.1002/art.41536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。